Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1 º Chemotherapy

Condition:   Head and Neck Cancer Interventions:   Drug: Paclitaxel;   Drug: Cetuximab + Paclitaxel Sponsors:   Grupo Español de Tratamiento de Tumores de Cabeza y Cuello;   Merck Sharp & Dohme Corp.;   Pivotal S.L. Terminated

Source: ClinicalTrials.gov - March 25, 2019 Category: Research Source Type: clinical trials